Patent 9873694 was granted and assigned to Janus Biotherapeutics Inc. on January, 2018 by the United States Patent and Trademark Office.
The present invention relates to a compound of Formula I: or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same.